MBCProject_0755_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.430
- OXIDATIVE_PHOSPHORYLATION+0.400
- PROTEIN_SECRETION+0.370
- ANDROGEN_RESPONSE+0.330
- FATTY_ACID_METABOLISM+0.290
- ANGIOGENESIS+0.250
- ESTROGEN_RESPONSE_LATE+0.210
- MTORC1_SIGNALING+0.210
- SPERMATOGENESIS+0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
Top 10 suppressed
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.460
- INTERFERON_GAMMA_RESPONSE-0.450
- INTERFERON_ALPHA_RESPONSE-0.430
- E2F_TARGETS-0.420
- MITOTIC_SPINDLE-0.420
- TGF_BETA_SIGNALING-0.340
- WNT_BETA_CATENIN_SIGNALING-0.330
- NOTCH_SIGNALING-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1144 | — | — | 0.825 |
| 2 | SRR8518241 | — | F | 0.810 |
| 3 | SRR1318426 | GTEX | — | 0.794 |
| 4 | SRR1471817 | GTEX | — | 0.785 |
| 5 | SRR8518242 | — | F | 0.781 |
| 6 | TCGA-A7-A0DB-01A-11R-A00Z-07 | — | A | 0.779 |
| 7 | SRR8518189 | — | F | 0.778 |
| 8 | TCGA-AO-A12G-01A-11R-A10J-07 | — | A | 0.776 |
| 9 | C3L-01632 | — | cohortA4 | 0.775 |
| 10 | SRR1420493 | GTEX | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |